Consensus development conference on antipsychotic drugs and obesity and diabetes: Response to consensus statement [4] (multiple letters)

Diabetes Care

Volumn 27, Issue 8, 2004, Pages 2086-2090

  Holt, Richard I G ^a,b   Citrome, Leslie ^c   Volavka, Jan ^c   Isaac, Michael T ^d   Isaac, Maria B ^d   Boehm, Gerard ^e   Racoosin, Judith A ^e,f   Laughren, Thomas P ^e   Katz, Russell ^e   Barrett, Eugene J ^g  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f Ladywell Unit ^*  (United States)

^g UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL TRIAL; CONSENSUS; DIABETES MELLITUS; DRUG EFFICACY; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LETTER; LIFESTYLE; MENTAL DISEASE; OBESITY; PATIENT MONITORING; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SUBSTANCE ABUSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CONSENSUS DEVELOPMENT CONFERENCES; DIABETES MELLITUS; HUMANS; OBESITY;

EID: 3343015504     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.8.2086     Document Type: Letter

References (0)